• Explore /
  • Poster
  • / A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.

Abstract Poster

Authors

null

Jeffrey A. Zonder

Karmanos Cancer Institute, Detroit, MI

Jeffrey A. Zonder , Noopur S. Raje , Emma Catherine Scott , Craig C. Hofmeister , Nikoletta Lendvai , Larry Don Anderson , Parameswaran Hari , Gregory Joshua Orloff , Jesus G. Berdeja , Seema Singhal , Michael Craig , Jason Neil Valent , Mieke Ptaszynski , Jennifer Schreiber , Roger Aitchison , Saad Zafar Usmani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01989325

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS8612)

DOI

10.1200/jco.2015.33.15_suppl.8612

Abstract #

TPS8612

Poster Bd #

424b

Abstract Disclosures

Similar Posters

First Author: Andrew Jenho Yee

First Author: Ravi Vij

First Author: Andrew J Yee

First Author: Krish Patel